Peoples Bank OH Has $398,000 Stock Holdings in Stryker Co. (NYSE:SYK)

Peoples Bank OH decreased its position in shares of Stryker Co. (NYSE:SYK) by 12.9% during the 4th quarter, HoldingsChannel.com reports. The fund owned 1,105 shares of the medical technology company’s stock after selling 163 shares during the period. Peoples Bank OH’s holdings in Stryker were worth $398,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in SYK. Foundations Investment Advisors LLC boosted its position in Stryker by 10.0% in the third quarter. Foundations Investment Advisors LLC now owns 1,753 shares of the medical technology company’s stock valued at $633,000 after buying an additional 160 shares in the last quarter. Sequoia Financial Advisors LLC boosted its position in Stryker by 1.7% in the third quarter. Sequoia Financial Advisors LLC now owns 11,236 shares of the medical technology company’s stock valued at $4,059,000 after buying an additional 187 shares in the last quarter. Stanley Laman Group Ltd. boosted its position in Stryker by 83.4% in the third quarter. Stanley Laman Group Ltd. now owns 1,379 shares of the medical technology company’s stock valued at $498,000 after buying an additional 627 shares in the last quarter. Private Advisor Group LLC boosted its position in Stryker by 3.4% in the third quarter. Private Advisor Group LLC now owns 15,967 shares of the medical technology company’s stock valued at $5,768,000 after buying an additional 526 shares in the last quarter. Finally, Commerzbank Aktiengesellschaft FI boosted its position in Stryker by 141.4% in the third quarter. Commerzbank Aktiengesellschaft FI now owns 3,577 shares of the medical technology company’s stock valued at $1,292,000 after buying an additional 2,095 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Morgan Stanley upgraded shares of Stryker from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $370.00 to $445.00 in a research report on Monday, December 2nd. Evercore ISI lifted their price target on shares of Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Stifel Nicolaus lifted their price target on shares of Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a report on Wednesday, January 29th. Wells Fargo & Company lifted their price target on shares of Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. Finally, JMP Securities reiterated a “market perform” rating on shares of Stryker in a report on Tuesday. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and a consensus price target of $420.68.

Insider Buying and Selling at Stryker

In other Stryker news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Stryker Price Performance

Shares of NYSE SYK opened at $386.47 on Friday. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The firm has a fifty day simple moving average of $377.92 and a 200 day simple moving average of $368.21. The company has a market capitalization of $147.47 billion, a PE ratio of 49.80, a P/E/G ratio of 2.93 and a beta of 0.96. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the prior year, the company earned $3.46 earnings per share. On average, sell-side analysts forecast that Stryker Co. will post 13.49 EPS for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.87%. The ex-dividend date is Monday, March 31st. Stryker’s dividend payout ratio (DPR) is currently 43.30%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.